Objective
programmed death, Cancer
CERVICAL CANCER, CANCER
Edited by: Fanping Meng, Fifth Medical Center of the PLA General Hospital, ChinaReviewed by: Rachael Rowswell-Turner, University of Rochester, United States; Chel Hun Choi, Samsung, Republic of Korea†These authors have contributed equally to this work and share first authorshipThis article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in ImmunologyWe report the efficacy and safety of serplulimab, a novel humanized anti–programmed death-1 antibody, plus nanoparticle albumin-bound (nab)-paclitaxel in previously treated patients with programmed death ligand-1 (PD-L1)–positive advanced cervical cancer.